NVSEF Quote, Financials, Valuation and Earnings

Kuros Biosciences Ltd. has a net margin of 18.03% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 32.34% beat Kuros Biosciences Ltd.'s return on equity of -6.35%.

Novartis AG has a consensus price target of --, signalling downside risk potential of -51.54%. On the other hand Kuros Biosciences Ltd. has an analysts' consensus of -- which suggests that it could fall by --. Given that Novartis AG has higher upside potential than Kuros Biosciences Ltd., analysts believe Novartis AG is more attractive than Kuros Biosciences Ltd..

Novartis AG has a beta of 0.488, which suggesting that the stock is 51.217% less volatile than S&P 500. In comparison Kuros Biosciences Ltd. has a beta of 0.913, suggesting its less volatile than the S&P 500 by 8.678%.

Novartis AG has a quarterly dividend of $3.96 per share corresponding to a yield of 2.31%. Kuros Biosciences Ltd. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 61.77% of its earnings as a dividend. Kuros Biosciences Ltd. pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.3B, which are larger than Kuros Biosciences Ltd. quarterly revenues of --. Novartis AG's net income of $2.4B is higher than Kuros Biosciences Ltd.'s net income of --. Notably, Novartis AG's price-to-earnings ratio is 23.93x while Kuros Biosciences Ltd.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 6.13x versus 9.78x for Kuros Biosciences Ltd.. Usually stocks with elevated PS ratios are considered overvalued.

EvoNext Holdings SA has a net margin of 18.03% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 32.34% beat EvoNext Holdings SA's return on equity of --.

Novartis AG has a consensus price target of --, signalling downside risk potential of -51.54%. On the other hand EvoNext Holdings SA has an analysts' consensus of -- which suggests that it could fall by --. Given that Novartis AG has higher upside potential than EvoNext Holdings SA, analysts believe Novartis AG is more attractive than EvoNext Holdings SA.

Novartis AG has a beta of 0.488, which suggesting that the stock is 51.217% less volatile than S&P 500. In comparison EvoNext Holdings SA has a beta of -42.013, suggesting its less volatile than the S&P 500 by 4301.301%.

Novartis AG has a quarterly dividend of $3.96 per share corresponding to a yield of 2.31%. EvoNext Holdings SA offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Novartis AG pays 61.77% of its earnings as a dividend. EvoNext Holdings SA pays out -- of its earnings as a dividend. Novartis AG's payout ratio is sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.3B, which are larger than EvoNext Holdings SA quarterly revenues of --. Novartis AG's net income of $2.4B is higher than EvoNext Holdings SA's net income of --. Notably, Novartis AG's price-to-earnings ratio is 23.93x while EvoNext Holdings SA's PE ratio is 5.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 6.13x versus 0.61x for EvoNext Holdings SA. Usually stocks with elevated PS ratios are considered overvalued.

Roche Holding AG has a net margin of 18.03% compared to Novartis AG's net margin of --. Novartis AG's return on equity of 32.34% beat Roche Holding AG's return on equity of 28.65%.

Novartis AG has a consensus price target of --, signalling downside risk potential of -51.54%. On the other hand Roche Holding AG has an analysts' consensus of $58.80 which suggests that it could fall by -0.39%. Given that Novartis AG has more downside risk than Roche Holding AG, analysts believe Roche Holding AG is more attractive than Novartis AG.

Novartis AG has a beta of 0.488, which suggesting that the stock is 51.217% less volatile than S&P 500. In comparison Roche Holding AG has a beta of 0.440, suggesting its less volatile than the S&P 500 by 56.044%.

Novartis AG has a quarterly dividend of $3.96 per share corresponding to a yield of 2.31%. Roche Holding AG offers a yield of 2.35% to investors and pays a quarterly dividend of $1.39 per share. Novartis AG pays 61.77% of its earnings as a dividend. Roche Holding AG pays out 58.07% of its earnings as a dividend. Both of these payout ratios are sufficient to cover dividend payouts with earnings for the foreseeable future.

Novartis AG quarterly revenues are $13.3B, which are larger than Roche Holding AG quarterly revenues of --. Novartis AG's net income of $2.4B is higher than Roche Holding AG's net income of --. Notably, Novartis AG's price-to-earnings ratio is 23.93x while Roche Holding AG's PE ratio is 24.57x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Novartis AG is 6.13x versus 5.12x for Roche Holding AG. Usually stocks with elevated PS ratios are considered overvalued.